Technology
- Currently standard screening is available only for cancers of the breasts, lungs, prostate, cervix and colon as individual procedures.
- Having to undergo a separate screening test for each cancer type may be inconvenient as it may necessitate prior appointments and may involve wait times.
- There is an overall low compliance with screening procedures due to these and other factors.
- Further, there are several cancers, including aggressive types, for which screening is not currently offered.
- A simple non-invasive, non-radiological test which has the capability to detect single cancer or multiple types of cancers in asymptomatic individuals is an unmet clinical need.
- Such a test can effectively identify individuals who may benefit from screening procedures as well as additional follow-up.
- Such a test can also improve compliance with cancer screening and help improve early detection as well as early detection rates.
- Such a test can help expand the scope of early detection to include several aggressive cancers.
TriNetra™ cancer screening addresses these challenges.
About TriNetra™
Reliable Technology
TriNetra™ detects CTCs, which are known to be present (and detected ubiquitously) in most types of cancers called solid tumors. Several prior clinical studies, including DCG’s own acclaimed studies have shown that CTCs are detectable even in very early Stage 0 (in situ cancer) as well as Stage I and Stage II malignancies. CTCs are detected across all solid organ tumor types and subtypes, in men and women. CTCs do not exist in individuals without cancer. CTCs are undetectable in blood of patients with noncancerous (benign) tumors. Owing to these properties, CTCs have high accuracy for cancer detection.
Clinically Proven
TriNetra™ has been developed and validated by analysis of more than
40,000 samples in large cohort studies which have established its high accuracy.
TriNetra™ is currently available for:
TriNetra™ – Pragma
TriNetra™– Pragma is intended for early detection of cancers of the Lungs, Breasts (F), Stomach, Pancreas, Ovaries (F), Prostate (M), and Colon.
TriNetra™ – Breast (F)
TriNetra™ – Prostate (M)
TriNetra™ is a safe and reliable test that can help detect cancers more effectively, assisting physicians to make timely life-saving diagnostic and clinical management decisions.
- The performance characteristics (Accuracy, Sensitivity, Specificity, NPV, PPV, etc.) of the Test are shown based on the case-control clinical studies performed by the Company under strict protocols.
- Performance of the Test in the real-world setting has not yet been established and the Company makes no claims/representation that the real-world performance of the Test will be similar to that of the case-control clinical studies.
- The nature of the Test, the disease, and the analyte are subject to biological dynamics which may not be freely understood and persons opting for the Test must obtain sufficient advice from a qualified physician regarding the suitability of the Test for a given individual.